Skip to content

Early Identification of Warfarin Maintenance Dosage

Early Identification of Warfarin Maintenance Dose in Patients With Atrial Fibrillation: a Randomized Trial Evaluating a New Genotype-based Versus Usual Care Initiation of Treatment

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01178034
Enrollment
180
Registered
2010-08-09
Start date
2009-10-31
Completion date
2012-10-31
Last updated
2012-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Warfarin, Dose, Pharmacogenetic, INR

Brief summary

Initiation of warfarin therapy is problematic. The investigators goal was to evaluate if a new demographic/pharmacogenetic algorithm is better than a usual algorithm based on INR value at day five after four days of 5 mg/day warfarin. To this end patients with atrial fibrillation starting warfarin are randomized in two arms.

Detailed description

The objective of this randomized study is to evaluate the accuracy of a new demographic/pharmacogenetic as compared to usual warfarin dosing algorithm in predicting warfarin maintenance dose. In patients with atrial fibrillation starting anticoagulation, the loading dose of warfarin in the tested group is calculated on the basis of VKORC1 genotype and patient's body weight.The second day warfarin maintenance dose is calculated on the basis of surface area and CYP2C9, CYP4F2 e VKORC1 genotype. In the usual care group the maintenance dose at day 5 is calculated on the basis of a published algorithm (Pengo V, Am J Cardiol 2001). INR is checked on day 0, 5, 7, 9, 12, 15 and 19. Primary end-point of the trial is the number of INR outside the therapeutic range of 2.0 to 3.0. Secondary end-points are the number of changes in dose prescription, the difference between predicted and actual warfarin maintenance dose and thrombotic and bleeding events.

Interventions

GENETICCalculate warfarin dose using demographic/genetic algorithm

Age, body weight and genetic to calculate warfarin dosage

Sponsors

University of Padova
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>18 years * Indication to warfarin with INR between 2.0 and 3.0

Exclusion criteria

* Pregnancy * Drug interactions * Basal INR \> 1.2

Design outcomes

Primary

MeasureTime frameDescription
International Normalized Ratio (INR)Day 0, 5, 7, 9, 12, 15, 19.Number of INR outside the therapeutic range (INR 2.0-3.0)

Secondary

MeasureTime frame
Number of changes in warfarin dosageDay 0-19
Difference between predicted and actual warfarin maintenance doseDay 19
Thromboembolic and Bleeding complicationsDay 0-30

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026